PharmaCyte Biotech (NASDAQ:PMCB) Posts Earnings Results

PharmaCyte Biotech (NASDAQ:PMCB) released its quarterly earnings results on Friday. The company reported ($0.29) EPS for the quarter, Zacks reports.

PharmaCyte Biotech Stock Performance

PMCB traded up $0.05 during trading on Friday, hitting $1.72. The stock had a trading volume of 8,228 shares, compared to its average volume of 23,956. PharmaCyte Biotech has a twelve month low of $1.39 and a twelve month high of $2.58. The firm has a market capitalization of $13.21 million, a P/E ratio of 2.61 and a beta of -0.21. The company’s 50-day moving average price is $1.75 and its 200 day moving average price is $1.86.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.